Minibet 100

Indications

Ciprofibrate serves as a supplementary treatment alongside diet, exercise, and weight reduction for the following conditions:

• Severe hypertriglyceridemia with or without low HDL cholesterol.
• Mixed hyperlipidemia when a statin is unsuitable or not tolerated.

Pharmacology

Ciprofibrate reduces LDL and VLDL levels, thereby lowering triglyceride and cholesterol associated with these lipoproteins. It also boosts HDL cholesterol levels. The medication effectively treats hyperlipidemia linked to high LDL and VLDL concentrations, potentially reducing coronary heart disease risks.

Dosage & Administration

For adults, the recommended daily dose is 100 mg of Ciprofibrate, which should not be exceeded.

• Patients with moderate renal impairment (creatinine clearance 30-80 ml/min/1.73 m²) should take one tablet every other day, with careful monitoring.
• Avoid Ciprofibrate in severe renal impairment (creatinine clearance <30 ml/min/1.73 m²).
• Use cautiously in patients with impaired hepatic function; discontinue treatment if liver enzymes exceed three times the upper limit of normal or if cholestatic liver injury occurs.
• Elderly patients over 70 should take precautions similar to adults.
• Not recommended for pediatric use due to lack of established safety and efficacy.

Interactions

• Combination with other fibrates or HMG CoA reductase inhibitors increases the risk of myopathy, rhabdomyolysis, and myoglobinuria.
• Exercise caution when using Ciprofibrate with oral anticoagulants; adjust anticoagulant dosage based on INR levels.

Contraindications

Avoid Ciprofibrate if:

• Hypersensitivity to the active substance or excipients.
• Severe hepatic impairment.
• Severe renal impairment (creatinine clearance <30 ml/min/1.73 m²).
• Pregnant or lactating, or suspected pregnancy.
• Concurrent use with another fibrate.

Side Effects

Common side effects may include headache, dizziness, nausea, and myalgia. Less frequently reported are rash, alopecia, and fatigue.

Pregnancy & Lactation

Ciprofibrate is contraindicated during pregnancy and lactation due to lack of human data on safety.

Precautions & Warnings

• Avoid in patients with galactose intolerance, lactose deficiency, or glucose-galactose malabsorption.
• Monitor for myalgia/myopathy symptoms and promptly report any muscle pain, tenderness, or weakness.
• Perform periodic hepatic function tests, particularly during the first year of treatment.

Therapeutic Class

Ciprofibrate belongs to the therapeutic class of anti-hypertensive, other anti-anginal, and anti-ischemic drugs.

Storage Conditions

Store below 30°C, protect from light and moisture, and keep out of reach of children.